number of previous anti-TNF, use of concomitant DMARDs and prednisone, drug retention rate at 1 year was significantly better for ABA compared to anti-TNF (p=0.02) and for TCZ compared to anti-TNF (p=0.04), but no difference was found between TCZ and ABA (p=0.62) ( Figure) . Background: Abatacept (ABT) is a widely used biologic for treating rheumatoid arthritis (RA). Objectives: Concomitant use of intravenous corticosteroids with ABT infusion may contribute to achieve earlier remission and higher retention rates. Methods: We conducted a retrospective cohort study at St. Luke's International Hospital, Tokyo, Japan, from January 2010 to June 2016. Patients who met the 2010 ACR/EULAR classification criteria for RA and treated with ABT were included in the study. We excluded patients who use two or more biologics prior to initiation of ABT. Our primary outcome was treatment retention rates of ABT at week 24. Secondary outcomes were changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) during follow-up (week 0 vs. week 8). We compared these outcomes between the patients receiving concomitant intravenous methylprednisolone (mPSL) with first 3 consecutive doses of ABT and those not receiving it. Log-rank analysis and Fisher's exact test were applied for statistical analysis. Results: 64 RA patients were included in the study. Mean age was 67.3 (± 14.2) and 55 (85.9%) were female. Among them, 13 (20.3%) received concomitant ABT with mPSL. The dosage of mPSL ranged from 30mg to 250mg (median dosage was 40mg). At week 24, the cumulative retention rates of the patients receiving mPSL (mPSL group) and those not receiving it (non-mPSL group) were 92.3% and 76.5%, respectively. There was no significant difference in the retention rates between the two groups (log-rank test, p=0.21) (figure). Changes in CRP between week 0 vs. week 8 were -1.56 mg/dl (± 2.92) in mPSL group and -1.08 mg/dl (± 2.17) in non-mPSL group (p=0.22), and those in ESR were -8.23 mm/h (± 18.40) in mPSL group and -6.61 mm/h (± 17.93) in non-mPSL group (p=0.75), respectively.
Conclusions: This is the first real world study to investigate whether ABT administrated with intravenous mPSL maintain higher retention rates in rheumatoid arthritis. Though there was no statistically significant difference, the retention rates of ABT at 24 weeks were higher among patients receiving ABT and mPSL concomitantly, compared with ABT mono-therapy group. It may reflect rapid improvement of the disease activity. Background: For rheumatoid arthritis (RA) patients who discontinue the first biologic agent (bDMARD), most commonly being a TNF inhibitor (TNFi), there is little evidence supporting the next best choice between a second TNFi course or a non-TNFi bDMARD in clinical practice. Objectives: To compare the effectiveness and the adherence to therapy with non-TNFi versus TNFi administered as the second-line bDMARD in RA patients with one prior TNFi use. Methods: All patients starting a bDMARD in the Rheumatology Department of the University Hospital of Heraklion, Crete, are included in a prospective observational study after their written informed consent. Data concerning disease activity at pre-specified time-points, drugs, comorbidities and any adverse events are recorded. For the present study we analyzed patients with RA starting their second course of a bDMARD after discontinuation of a TNFi. We compared DAS28 difference at 6 and 12 months using linear regression analysis and treatment retention using Kaplan-Meier survival curves with log-rank test. Table. Two-year drug survival was higher for non-TNFi (64% vs. 39%, log rank p<0.001) due to lower frequency of discontinuations for primary failure (p<0.001) and adverse events (p=0.019). δDAS28 was comparable between non-TNFi and TNFi patient groups both at 6 [mean (SD): -1.16 (1.29) and -1.07 (1.55) respectively, p=0.296] and at 12 months [-1.41 (1.29) and -1.39 (1.26) respectively, p=0.670]. In patients who did not receive co-therapy with methotrexate, significantly greater δDAS28 was observed with a non-TNFi (-1.25 (1.29) vs.-0.68 (1.61), p=0.006). When the first TNFi was discontinued due to primary failure, we observed a trend for greater δDAS28 in the non-TNFi patient group compared to the 2nd TNFi group (-1.4 vs. -1.0, p=0.12) while the opposite was observed in patients who have experienced secondary failure to the 1st TNFi (-0.81 vs -1.48, p=0.18), but this did not reach statistical significance, probably due to the low number of available patients. Conclusions: In RA patients who need a 2nd bDMARD after discontinuation of a TNFi, administration of a non-TNFi results in similar clinical responses but higher treatment adherence compared to a second TNFi agent. In patients who do not receive methotrexate, responses are better with a non-TNFi bDMARD. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6817
